Gilead Sciences to Buy Ouro Medicines for $1.68 Billion Upfront
Gilead Sciences has plans to acquire Ouro Medicines based in South San Francisco, California. The transaction, which was announced on March 24, includes an upfront payment of approximately $1.68 billion, along with up to $500 million in milestone-based payments linked...Cap Rates Continue Compression in JLL’s Investor Survey
Ben Swett, Managing Editor of The SeniorCare Investor, sat down with Bryan Lockard, Executive Managing Director of JLL‘s Value and Risk Advisory, to discuss the results of JLL’s recently published 2026 Seniors Housing & Care Investor Survey and Trends. They also...60 Seconds with Swett: Burning Questions for NIC Attendees
This time next week, we’ll be heading out of Nashville from the Spring NIC conference likely buoyed by the overwhelmingly positive mood we’re expecting from most of our industry friends. It’s hard not to be optimistic when occupancy and margins are increasing to...The Money Always Wins: A Healthcare Webinar Wrap Up
Last week, Ben Swett, Managing Editor of The SeniorCare Investor, was joined by John Tiedmann, Managing Director at Physician Growth Partners, Bill Hoffman, Shareholder at Polsinelli and Matt Bogle, Managing Director at Intrinsic, to discuss the trends facing the...Retina Consultants of America Announces $1.1 Billion Acquisition
On March 23, Cencora announced that its portfolio company, Retina Consultants of America (RCA), entered into an agreement to acquire EyeSouth Partners’ retina business. The purchase price is $1.1 billion, marking the largest eye care purchase price in the last five...Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
